Calliditas Therapeutics (CALT)
(Delayed Data from NSDQ)
$40.88 USD
+0.53 (1.31%)
Updated Aug 27, 2024 03:59 PM ET
4-Sell of 5 4
F Value A Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Calliditas Therapeutics AB Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 92 | 124 | 111 | 109 | 80 |
Receivables | 17 | 8 | 0 | 0 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 8 | 7 | 4 | 2 |
Total Current Assets | 120 | 140 | 118 | 113 | 87 |
Net Property & Equipment | 2 | 1 | 1 | 0 | 0 |
Investments & Advances | 2 | 1 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 2 | 1 | 0 | 0 | 0 |
Intangibles | 45 | 48 | 47 | 50 | 2 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 175 | 194 | 170 | 164 | 89 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 16 | 8 | 6 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 26 | 14 | 6 | 5 | 3 |
Income Taxes Payable | 1 | 1 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 1 | 1 | 0 |
Total Current Liabilities | 38 | 32 | 16 | 12 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 4 | 4 | 9 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 89 | 71 | 22 | 0 | 0 |
Non-Current Capital Leases | 3 | 2 | 3 | 0 | 0 |
Other Non-Current Liabilities | 10 | 9 | 8 | 7 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 144 | 118 | 53 | 27 | 6 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 249 | 257 | 287 | 233 | 135 |
Retained Earnings | -217 | -182 | -166 | -100 | -52 |
Other Equity | 0 | 1 | -3 | 4 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 32 | 76 | 118 | 137 | 83 |
Total Liabilities & Shareholder's Equity | 175 | 194 | 170 | 164 | 89 |
Total Common Equity | 32 | 76 | 118 | 137 | 83 |
Shares Outstanding | 29.70 | 29.70 | 26.10 | 23.90 | NA |
Book Value Per Share | 1.06 | 2.56 | 4.50 | 5.73 | 0.00 |
Fiscal Year End for Calliditas Therapeutics AB Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 74 | 78 | 92 | 73 | 82 |
Receivables | 21 | 18 | 17 | 12 | 14 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 3 | 2 | 1 | 2 |
Other Current Assets | 9 | 7 | 9 | 9 | 8 |
Total Current Assets | 108 | 106 | 120 | 96 | 106 |
Net Property & Equipment | 2 | 2 | 2 | 1 | 1 |
Investments & Advances | 3 | 2 | 2 | 2 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 3 | 3 | 2 | 2 | 2 |
Intangibles | 44 | 45 | 45 | 44 | 49 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 163 | 162 | 175 | 149 | 162 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 10 | 9 | 6 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 24 | 26 | 26 | 23 | 18 |
Income Taxes Payable | 0 | 0 | 1 | 0 | 0 |
Other Current Liabilities | 2 | 3 | 2 | 2 | 3 |
Total Current Liabilities | 40 | 39 | 38 | 32 | 28 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 3 | 3 | 4 | 4 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 92 | 95 | 89 | 69 | 72 |
Non-Current Capital Leases | 2 | 3 | 3 | 3 | 2 |
Other Non-Current Liabilities | 15 | 10 | 10 | 9 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 153 | 151 | 144 | 117 | 114 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 0 | 0 | 249 | 0 | 0 |
Retained Earnings | 0 | 0 | -217 | 0 | 0 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 10 | 12 | 32 | 33 | 48 |
Total Liabilities & Shareholder's Equity | 163 | 162 | 175 | 149 | 162 |
Total Common Equity | 10 | 12 | 32 | 33 | 48 |
Shares Outstanding | 29.70 | 29.70 | 29.70 | 29.70 | 29.70 |
Book Value Per Share | 0.34 | 0.39 | 1.06 | 1.10 | 1.61 |